B01D15/3847

Apatite pretreatment
09802822 · 2017-10-31 · ·

Apatite pretreatment methods are provided. The method is applied to the apatite solid surface prior to first chromatographic use. In one embodiment, the method may be achieved by contacting an apatite solid surface with a phosphate buffered solution at a pH of at least about 6.5 and contacting the apatite solid surface with a solution having a hydroxide.

Universal blood product and methods of preparing and using same

A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; and recovering the cleansed product. A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; wherein at least one of the hydroxyapatite, carbonaceous material and support matrix is functionalized.

ISOLATION OF SOLUBLE PROTEINS FROM AGGREGATED CASEIN-CONTAINING MIXTURES

The present invention relates to a method for separating at least one soluble protein fraction from an aggregated casein-containing material, the method comprises the steps of: (i) providing the aggregated casein-containing material; (ii) Contacting the aggregated casein-containing material with a chromatographic support allowing one or more soluble protein(s) present in the aggregated casein-containing material to be retained by the chromatographic support; (iii) Obtaining a permeate fraction from the chromatographic support comprising aggregated casein; (iv) Optionally washing the chromatographic support; (v) Subjecting the chromatographic support to at least one elution buffer obtaining at least one soluble protein fraction from the chromatographic support; and wherein the chromatographic support comprises one or more mixed-mode ligands capable of binding the soluble proteins from the aggregated casein-containing material.

Removal of high molecular weight aggregates using hydroxyapatite chromatography
09822143 · 2017-11-21 · ·

This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.

Removal of high molecular weight aggregates using hydroxyapatite chromatography
09822143 · 2017-11-21 · ·

This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.

Continuous sample purification systems and methods

Sample purification systems include a particle extraction assembly having a mixing compartment and a settling compartment. A biological sample is mixed with two liquid phases formulated to effectuate transfer of a biological molecule into a first phase and particulate contaminants into a second phase. The first phase includes a solubilizing salt, the second phase includes an organic molecule, and the mixture can have little or no monoatomic salt or dextran. The molecule-containing first phase can be optionally concentrated without also concentrating the particulate contaminants and introduced into a multi-stage liquid-liquid extractor, by which the biological molecule or molecular contaminants are extracted from the first phase into a third phase, thereby purifying the molecule away from contaminants. The extracted sample can be further purified through a series of processing steps. The system can be run in continuously mode to maintain sterility of the sample.

DEVICE FOR SOLID PHASE EXTRACTION AND METHOD FOR USE THEREOF

Disclosed is a device for a solid phase extraction comprising two or more of the sorbents to remove phospholipids and salts from a sample, to thereby eliminate matrix effects during mass spectrometry analysis. In particular, the sorbents includes at least one sorbent which is water-wettable and contains at least one hydrophobic component and at least one hydrophilic component and at least one of sorbent having a specific affinity for a matrix interference like phospholipids. Further disclosed is a method using the device of the present invention.

IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM
20220306678 · 2022-09-29 ·

Provided herein are methods for purification of RNA from a sample. The methods include obtaining a first sample including double stranded RNA in a loading buffer, loading the sample onto a ceramic hydroxyapatite column, washing the column with wash buffer, and eluting the column with an elution buffer to create an eluate.

MICROSCALE BIOPROCESSING SYSTEM AND METHOD FOR PROTEIN MANUFACTURING FROM HUMAN BLOOD

A bioprocessing system for protein manufacturing from human blood is provided that is compact, integrated and suited for on-demand production and delivery of therapeutic proteins to patients. The patient's own blood can be used as the source of cell extracts for the production of the therapeutic proteins.

MIXED MODE CATION EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON 1,3-DIOXOISOINDOLIN-2-YL STRUCTURES
20220305460 · 2022-09-29 ·

The subject invention pertains to proteins are purified by a mixed-mode chromatography system formed by attaching a ligand with cation exchange and hydrophobic 1,3-droxoisoindolin-2-yl group functionalities to a large-pore support matrix, the only linkage between the ligand and the support matrix being a chain having a backbone of one, two, three, four, or five atoms between the hydrophobic group and the support matrix.